An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Uncontrolled Severe Chronic Pain Due to Osteoarthritis of the Knee Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
Latest Information Update: 24 Oct 2019
Price :
$35 *
At a glance
- Drugs Tapentadol (Primary)
- Indications Osteoarthritis; Pain
- Focus Registrational; Therapeutic Use
- Sponsors Grunenthal
- 01 Mar 2012 Actual patient number 224 added as reported by ClinicalTrials.gov record.
- 20 Sep 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 20 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.